Ibiglustat succinate

• CAT Number: I029038
• CAS Number: 1629063-80-4
• Molecular Formula: C24H30FN3O6S
• Molecular Weight: 507.57
• Purity: ≥95%
• Synonyms: [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate;butanedioic acid
• InChI: InChI=1S/C20H24FN3O2S.C4H6O4/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24;5-3(6)1-2-4(7)8/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25);1-2H2,(H,5,6)(H,7,8)/t16-;/m1./s1
• InChIKey: TWRYSLPYKQOKAO-PKLMIRHRSA-N
• SMILES: CC(C)(C1=CSC(=N1)C2=CC=C(C=C2)F)NC(=O)O[C@@H]3CN4CCC3CC4.C(CC(=O)O)C(=O)O

Ibiglustat Succinate（Cat No.:I029038）is an investigational glucosylceramide synthase inhibitor developed for lysosomal storage disorders like Gaucher disease. By inhibiting the synthesis of glycosphingolipids, it helps reduce the accumulation of toxic substrates in lysosomes. Its oral bioavailability offers a convenient alternative to enzyme replacement therapies. Ibiglustat succinate may cross the blood–brain barrier, making it a potential candidate for neuronopathic forms of lysosomal diseases. Preclinical and early clinical studies have demonstrated favorable pharmacokinetics and safety profiles.